Literature DB >> 22744640

Overview of personalized medicine in GI cancers.

Celia Chao1.   

Abstract

Cancer biomarkers may be used for prevention (identification of patients at high risk for cancer), estimating prognosis and/or repsonse to conventional chemotherapies, or guide the use of specific targeted therapies. This overview provides examples in each category for gastrointestinal cancers and reviews current concepts in personalized medicine.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22744640      PMCID： PMC3761351          DOI： 10.1007/s11605-012-1949-8

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN： 1091-255X            Impact factor:   3.452


  15 in total

1.  Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.

Authors:  Michael J O'Connell; Ian Lavery; Greg Yothers; Soonmyung Paik; Kim M Clark-Langone; Margarita Lopatin; Drew Watson; Frederick L Baehner; Steven Shak; Joffre Baker; J Wayne Cowens; Norman Wolmark
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

Review 2.  ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.

Authors:  José G Guillem; William C Wood; Jeffrey F Moley; Andrew Berchuck; Beth Y Karlan; David G Mutch; Robert F Gagel; Jeffrey Weitzel; Monica Morrow; Barbara L Weber; Francis Giardiello; Miguel A Rodriguez-Bigas; James Church; Stephen Gruber; Kenneth Offit
Journal:  Ann Surg Oncol       Date:  2006-10       Impact factor: 5.344

3.  The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.

Authors:  Foluso O Ademuyiwa; Austin Miller; Tracey O'Connor; Stephen B Edge; Mangesh A Thorat; George W Sledge; Ellis Levine; Sunil Badve
Journal:  Breast Cancer Res Treat       Date:  2011-01-01       Impact factor: 4.872

Review 4.  Risk of breast and ovarian cancer in women with strong family histories.

Authors:  A Srivastava; W McKinnon; M E Wood
Journal:  Oncology (Williston Park)       Date:  2001-07       Impact factor: 2.990

5.  Cetuximab for the treatment of colorectal cancer.

Authors:  Derek J Jonker; Chris J O'Callaghan; Christos S Karapetis; John R Zalcberg; Dongsheng Tu; Heather-Jane Au; Scott R Berry; Marianne Krahn; Timothy Price; R John Simes; Niall C Tebbutt; Guy van Hazel; Rafal Wierzbicki; Christiane Langer; Malcolm J Moore
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

6.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

Review 7.  Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

Authors:  Kathy S Albain; Soonmyung Paik; Laura van't Veer
Journal:  Breast       Date:  2009-10       Impact factor: 4.380

8.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Authors:  Ronald P Dematteo; Karla V Ballman; Cristina R Antonescu; Robert G Maki; Peter W T Pisters; George D Demetri; Martin E Blackstein; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Shreyaskumar Patel; Martin D McCarter; Jonathan A Polikoff; Benjamin R Tan; Kouros Owzar
Journal:  Lancet       Date:  2009-03-18       Impact factor: 79.321

9.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Authors:  Federica Di Nicolantonio; Miriam Martini; Francesca Molinari; Andrea Sartore-Bianchi; Sabrina Arena; Piercarlo Saletti; Sara De Dosso; Luca Mazzucchelli; Milo Frattini; Salvatore Siena; Alberto Bardelli
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

10.  BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status.

Authors:  Wei Qi Li; Kazuyuki Kawakami; Andrew Ruszkiewicz; Graeme Bennett; James Moore; Barry Iacopetta
Journal:  Mol Cancer       Date:  2006-01-10       Impact factor: 27.401
View more
  1 in total

Review 1.  From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors.

Authors:  Federica Zoratto; L Rossi; E Giordani; M Strudel; A Papa; S Tomao
Journal:  Tumour Biol       Date:  2014-07-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.